HIV treatment has seen significant advancements over the past few decades. HIV/AIDS was first recognized in the early 1980s. At that time, the medical community faced an extraordinary challenge. No effective treatments were available. Early approaches were limited to supportive care and symptomatic treatment.
These offered little hope for long-term survival. In 1996, highly active antiretroviral therapy (HAART) was introduced. This revolutionized HIV care by combining multiple drugs. It helped suppress the virus and improve patient outcomes.
Antiretroviral therapy (ART) has improved over time. New drugs work better and have fewer side effects. The dosing schedules are now simpler. However, challenges still exist. It is still hard to achieve and maintain viral suppression. Managing drug interactions is also a problem. Ensuring that patients stick to their treatment is a major concern.
Introduction to Biktarvy
Biktarvy is an antiretroviral drug that controls HIV-1 in the body. It combines three drugs—bictegravir, Emtricitabine, and Tenofovir Alafenamide—into one tablet. These ingredients work together to stop the virus from multiplying, lowering the viral load in the bloodstream, and helping protect the immune system. People with HIV can live healthier and longer lives with Biktarvy. While it is not a cure for HIV, it is essential for managing the disease. It also helps prevent HIV from progressing to AIDS.
Biktarvy is especially helpful for those who have never received HIV treatment. It also works well for those whose virus is not resistant to the drug. Biktarvy helps keep the viral load undetectable. This keeps individuals healthy and lowers the risk of spreading the virus to others.
Biktarvy was approved by the U.S. Food and Drug Administration (FDA) on February 7, 2018. Since then, it has become widely available in many countries. Its single-tablet regimen is popular among healthcare providers and patients. This is because it is simple and effective.
Composition and Formulation of Biktarvy
Biktarvy is a fixed-dose combination tablet designed to manage HIV-1 infection. It contains three active ingredients: Bictegravir, Emtricitabine, and Tenofovir Alafenamide. Each ingredient targets different stages of the HIV replication cycle. Together, they help suppress the virus.
Bictegravir
Role in HIV Management: Bictegravir is an integrase strand transfer inhibitor (INSTI). It stops the integrase enzyme, which is needed to integrate viral DNA into the host cell's genome. This prevents the virus from establishing a permanent infection.
- Mechanism of Action: Bictegravir binds to the integrase enzyme’s active site. This blocks the transfer of viral DNA into the host cell’s DNA, stopping viral replication.
- Effect on Resistance: Bictegravir has a high barrier to resistance. It is less likely to be affected by mutations, helping maintain long-term viral suppression.
Emtricitabine
Role in HIV Management: Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI). It mimics the building blocks of viral RNA. When incorporated into viral DNA, it acts as a chain terminator, halting viral DNA elongation.
- Mechanism of Action: Emtricitabine competes with the reverse transcriptase enzyme, which converts viral RNA into DNA. This blocks the replication of HIV.
- Effect on Resistance: Emtricitabine is effective against HIV strains resistant to other NRTIs. Its presence in Biktarvy ensures a broader range of activity against different HIV strains.
Tenofovir Alafenamide
Role in HIV Management: Tenofovir Alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI). It is a prodrug of Tenofovir, which becomes active once inside the host cell. It inhibits the reverse transcriptase enzyme, similar to Emtricitabine.
- Mechanism of Action: After being converted to Tenofovir, TAF blocks viral replication by terminating the viral DNA chain.
- Effect on Resistance: TAF causes fewer renal and bone side effects than Tenofovir Disoproxil Fumarate (TDF). This makes TAF a better option for long-term therapy.
Significance of Biktarvy in HIV Treatment
Biktarvy stands out for several reasons
- Efficacy: Clinical trials have shown that Biktarvy is highly effective at achieving viral suppression. It works well in both treatment-naïve and experienced patients. The combination of agents in Biktarvy has produced better results compared to older regimens.
- Convenience: Biktarvy is a single-tablet regimen. This makes it easier for patients to follow their treatment plan. It reduces the need to manage multiple medications, simplifying adherence.
- Safety Profile: The inclusion of TAF in Biktarvy reduces the risk of long-term side effects. This is especially true for kidney and bone issues, which were familiar with earlier tenofovir formulations.
Who Should Take Biktarvy?
Biktarvy is prescribed for people who are HIV-1 positive. It is especially recommended for those who are treatment-naive. This means they have not started any antiretroviral therapy. Biktarvy is suitable for adults and children aged 2 years or older. Children must weigh at least 14 kg to take the medication.
For people with co-existing conditions, Biktarvy may still be an option. However, it requires careful consideration. Those with kidney or liver problems need monitoring. This is because Tenofovir Alafenamide can affect these organs. Biktarvy is also safer for cardiovascular health compared to treatments containing Abacavir.
Pregnant or breastfeeding individuals should consult their healthcare provider before starting Biktarvy.
Dosage and Administration
- Standard Dosage: Take one Biktarvy tablet once a day. This dose is the same for adults and children who weigh at least 14 kg. There is no need to adjust the dose based on weight. Always follow your doctor’s advice. You don’t need to take Biktarvy with food, which makes it more convenient for daily use. It’s important to take Biktarvy at the same time each day to maintain consistent levels of the medication in your body.
- Missed Dose Instructions: If you forget a dose, take it as soon as you remember. If it’s almost time for your next dose, skip the missed one. Stick to your regular schedule. Don’t take two doses at once to make up for a missed dose. This can increase the risk of side effects. If you often forget doses, talk to your healthcare provider for tips to stay on track.
Important Tips for Proper Use:
- Do not skip doses: Taking Biktarvy as prescribed is essential. Missing doses can lead to drug resistance and reduce its effectiveness.
- Avoid certain medications: Antacids containing aluminum or magnesium can interfere with Biktarvy’s absorption. Always tell your doctor about any other medications or supplements you are taking.
- Stay hydrated: Biktarvy is generally well-tolerated, but drinking plenty of water supports kidney function.
Benefits of Biktarvy
- Efficacy in Managing HIV: Biktarvy is highly effective in managing HIV. It reduces the viral load to undetectable levels. Research shows that over 90% of individuals using Biktarvy achieve viral suppression. This means the virus becomes untraceable in their bloodstream. Achieving viral suppression helps prevent the progression of HIV. It also reduces the risk of transmitting the virus to others.
- Convenience (Once-Daily Tablet): Biktarvy combines three powerful HIV medications into one daily tablet. This simplifies treatment and minimizes the pill burden. The single-tablet approach makes it easier to stick to medication routines. Consistent adherence is key to long-term HIV management.
- Long-Term Benefits for the Immune System: Biktarvy helps control the virus, which supports a healthy immune system. A strong immune system is crucial for preventing infections and diseases. Long-term use of Biktarvy improves quality of life and lowers the risk of HIV-related complications.
Side Effects and Management Strategies
Like all medications, Biktarvy may cause side effects, though many people tolerate it well. Some of the most common side effects include
Common Side Effects:
- Nausea
Management - Take Biktarvy with food to help prevent nausea. Ginger or peppermint tea can ease mild nausea. If nausea continues, talk to a healthcare provider about anti-nausea medications.
- Headache
Management: Use over-the-counter pain relievers such as acetaminophen or ibuprofen. Drink plenty of water and get enough rest. If you have frequent or severe headaches, consult a healthcare provider.
- Diarrhea
Management: Drink plenty of fluids to stay hydrated. You can take over-the-counter medicines like loperamide (Imodium) to relieve symptoms. If diarrhea persists or worsens, consult a healthcare provider. Eating bland foods and avoiding dairy may also help.
- Fatigue
Management - Get enough rest and eat a balanced diet. Regular exercise can boost your energy. If you feel very tired for a long time, talk to a doctor to check for other issues.
Serious Side Effects
- Hepatotoxicity
Management: Get regular liver function tests to monitor your liver health. Signs of liver damage include yellow skin or eyes (jaundice) and dark urine. If you notice these signs, consult a healthcare provider.
- Renal Impairment
Management - Kidney function tests are important for patients with existing kidney problems. Stay well-hydrated and avoid medications that can harm your kidneys. Report any unusual swelling or changes in urination to a healthcare provider.
- Bone Density Loss
Management - Regular bone density tests can track changes in your bones. Patients should do weight-bearing exercises and get enough calcium and vitamin D. Talk to a healthcare provider for personalized advice or medications to improve bone health.
Drug Interactions
Drug interactions can affect the efficacy and safety of medications. Managing these interactions is crucial to ensure the treatment works well and to avoid unwanted side effects.
- Antacids and Supplements
Interactions: Antacids containing magnesium or aluminum can reduce the absorption of tenofovir alafenamide. This may lower its effectiveness.
Calcium supplements may also impact the absorption of tenofovir alafenamide.
Management: Separate the intake of antacids or supplements by at least 4 hours from Biktarvy.
- Anticonvulsants
Interactions: Phenytoin, carbamazepine, and phenobarbital can induce liver enzymes (CYP3A4). This may decrease the efficacy of bictegravir.
Management: Consider alternative anticonvulsants that do not induce liver enzymes. Close monitoring for efficacy is recommended.
- Antifungal Agents
Interactions: Azole antifungals can increase bictegravir plasma concentrations by inhibiting CYP3A4.
Management: Monitor for increased side effects of Biktarvy. Adjust the dose if necessary.
- Antiretroviral Agents
Interactions: Ritonavir and cobicistat are potent CYP3A4 inhibitors. They can increase the levels of bictegravir and emtricitabine.
Management: Regular monitoring of drug levels and potential side effects is necessary.
- Proton Pump Inhibitors
Interactions: Omeprazole and esomeprazole can decrease the absorption of tenofovir alafenamide.
Management: Use H2-receptor antagonists or antacids instead of proton pump inhibitors, if possible.
- Statins
Interactions: Simvastatin and lovastatin are metabolized by CYP3A4. They can interact with bictegravir.
Management: Use lower doses of simvastatin or lovastatin. Alternatively, choose statins with fewer interactions.
Clinical Trial of Biktarvy
BIKTARVY has been tested in 5 clinical trials with over 2,900 adults living with HIV. This is the summary of how it was studied. Biktarvy is approved for use in over 60 countries worldwide, and more than 500,000 people globally have been treated with Biktarvy since its launch.
New to Treatment
In two studies, more than 1,200 adults who were starting HIV treatment were involved. Half of these adults started with BIKTARVY, and the other half tried different treatments, like TRIUMEQ or DESCOVY + TIVICAY. After 3 years, most of those on other treatments switched to BIKTARVY. These groups were then followed for an additional 2 years. This means BIKTARVY was studied in new patients for up to 5 years.
Switching Treatments
Two other studies included over 1,100 adults who either switched to BIKTARVY from their current treatment or continued with their existing treatment for 1 year. Half received their treatment with BIKTARVY, and the other half stayed on their current treatment, such as TRIUMEQ or a combination of EPZICOM or TRUVADA with another drug.
HIV Mutations
In one additional study, over 560 adults either switched to BIKTARVY or stayed on their current treatment (DESCOVY + TIVICAY). Of the 284 adults who switched to BIKTARVY, 47 had an HIV mutation called M184V/I that made the virus resistant to emtricitabine, one of the components of BIKTARVY. Despite this, BIKTARVY still worked effectively.
These studies showed that BIKTARVY works well across different ages, genders, and races.
Reaching and Staying Undetectable
Starting BIKTARVY: Clinical studies over 3 and 5 years have shown that most new patients who take BIKTARVY daily can achieve and maintain an "undetectable" viral load. This means the amount of HIV in their blood is so low that it cannot be measured (less than 50 copies/mL).
Increasing CD4 T-Cell Count: BIKTARVY can also help increase the number of CD4 T-cells, which are important for fighting infections and keeping the immune system strong.
Switching to BIKTARVY
Staying Undetectable: BIKTARVY helps people stay undetectable and maintain their CD4 T-cell count. It is also effective even if the HIV has a mutation called M184V/I, which makes it resistant to emtricitabine. Before starting BIKTARVY, your healthcare provider will ensure you meet certain requirements for using this medication.
Insurance Coverage and Assistance Programs
Insurance coverage for Biktarvy varies by health plan. Here are some essential points
- Health Insurance Plans: Many plans, including private insurance and Medicare Part D, cover Biktarvy. However, coverage levels, co-pays, and deductibles can differ.
- Formulary Status: Check if Biktarvy is on your insurance plan’s list of covered drugs. If not, your doctor may need to request coverage approval.
- Co-Pay Assistance: You may have co-pays or co-insurance even with insurance. The amount depends on your plan, and some plans may cover more.
Patient Assistance Programs
To help with the cost of Biktarvy, several assistance programs are available.
- Gilead Sciences Patient Assistance Programs: Gilead offers support for uninsured or underinsured patients. They provide financial help and guidance for accessing medications. Eligibility usually depends on income and insurance status.
- Non-Profit Organizations: Groups such as the Patient Advocate Foundation and the Ryan White HIV/AIDS Program offer financial assistance. They assist with insurance navigation and medication access. They may also help with co-pays and premiums based on eligibility.
- Pharmacy Assistance Programs: Some pharmacies have savings cards or discount programs to lower the cost of Biktarvy.
- State and Federal Programs: Medicaid often covers HIV medications, including Biktarvy, for eligible low-income individuals. Medicare Part D may also cover it. Check your plan’s formulary and talk to a Medicare counselor if needed.
References
